Glenn S. Vraniak
About Glenn S. Vraniak
Glenn S. Vraniak Chief Financial Officer
Glenn S. Vraniak is a seasoned Chief Financial Officer with extensive experience in the financial management of life sciences companies. His expertise includes leading organizations through major financial milestones such as initial public offerings (IPOs) on Nasdaq. He held the CFO title at both Evaxion Biotech A/S and electroCore, Inc., successfully guiding them through their respective IPOs. With over two decades in the industry, Vraniak combines robust financial acumen with substantial commercial experience.
Glenn S. Vraniak Education and Expertise
Glenn S. Vraniak holds an MBA in finance from Rutgers University Center for Management Development, equipping him with advanced financial management skills. In addition, he has an Electronic Engineering Technology degree, providing a technical foundation that complements his financial expertise. Vraniak's educational background supports his strategic approach to managing and guiding financial operations within the life sciences sector.
Glenn S. Vraniak Career Background
Glenn S. Vraniak has spent over 20 years in the life sciences industry, building a robust career in financial and commercial roles. His experience includes serving as an Executive Vice President at GE Capital, where he honed his financial leadership skills. Vraniak's career is marked by significant achievements in leading biotech companies like Evaxion Biotech A/S and electroCore, Inc., through successful IPOs on Nasdaq. His background reflects a strong blend of technical knowledge and financial strategy.
Glenn S. Vraniak Achievements
Throughout his career, Glenn S. Vraniak has achieved notable milestones, particularly in guiding biotech companies through successful IPOs. As the Chief Financial Officer at Evaxion Biotech A/S, he led the company through its IPO on Nasdaq in February 2021. Prior to this, he was the CFO at electroCore, Inc., contributing to their IPO on Nasdaq in June 2018. Vraniak's achievements highlight his ability to navigate complex financial landscapes and drive significant growth in the life sciences industry.